Esobon Injection contains Esomeprazole 40 mg, a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions involving excessive gastric acid secretion. Esomeprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing the final step in gastric acid production. This results in a significant and sustained reduction in gastric acidity, promoting healing of acid-related mucosal damage and providing symptomatic relief. Esobon Injection is administered intravenously, making it suitable for patients who are unable to take oral medications or require rapid acid suppression. The injection is typically used in hospital settings under medical supervision, with dosage and duration tailored according to the severity of the condition and patient response. Common adverse effects may include headache, nausea, abdominal pain, and injection site reactions, though it is generally well tolerated. Caution is advised in patients with hepatic impairment, and drug interactions should be considered due to Esomeprazole’s effect on gastric pH and cytochrome P450 enzymes. Esobon Injection provides an effective therapeutic option for managing acid-related disorders requiring parenteral administration.